JP2022542802A5 - - Google Patents

Info

Publication number
JP2022542802A5
JP2022542802A5 JP2022502209A JP2022502209A JP2022542802A5 JP 2022542802 A5 JP2022542802 A5 JP 2022542802A5 JP 2022502209 A JP2022502209 A JP 2022502209A JP 2022502209 A JP2022502209 A JP 2022502209A JP 2022542802 A5 JP2022542802 A5 JP 2022542802A5
Authority
JP
Japan
Prior art keywords
polypeptide
combination
pharmaceutical composition
composition according
polynucleotide encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022502209A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022542802A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/042453 external-priority patent/WO2021011844A2/en
Publication of JP2022542802A publication Critical patent/JP2022542802A/ja
Publication of JP2022542802A5 publication Critical patent/JP2022542802A5/ja
Priority to JP2025125676A priority Critical patent/JP2025166001A/ja
Pending legal-status Critical Current

Links

JP2022502209A 2019-07-17 2020-07-17 併用がん療法剤および方法 Pending JP2022542802A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025125676A JP2025166001A (ja) 2019-07-17 2025-07-28 併用がん療法剤および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962875230P 2019-07-17 2019-07-17
US62/875,230 2019-07-17
PCT/US2020/042453 WO2021011844A2 (en) 2019-07-17 2020-07-17 Combination cancer therapy agents and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025125676A Division JP2025166001A (ja) 2019-07-17 2025-07-28 併用がん療法剤および方法

Publications (2)

Publication Number Publication Date
JP2022542802A JP2022542802A (ja) 2022-10-07
JP2022542802A5 true JP2022542802A5 (enExample) 2023-10-02

Family

ID=74209956

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022502209A Pending JP2022542802A (ja) 2019-07-17 2020-07-17 併用がん療法剤および方法
JP2025125676A Pending JP2025166001A (ja) 2019-07-17 2025-07-28 併用がん療法剤および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025125676A Pending JP2025166001A (ja) 2019-07-17 2025-07-28 併用がん療法剤および方法

Country Status (4)

Country Link
US (1) US20220280609A1 (enExample)
EP (1) EP3999092A4 (enExample)
JP (2) JP2022542802A (enExample)
WO (1) WO2021011844A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022192323A1 (en) * 2021-03-09 2022-09-15 Board Of Regents, The University Of Texas System Low intensity ultrasound combination cancer therapies
WO2024103042A1 (en) * 2022-11-11 2024-05-16 University Of Florida Research Foundation, Incorporated Recombinant aav as an immune adjuvant
WO2025059507A1 (en) * 2023-09-15 2025-03-20 The Regents Of The University Of California Combination cancer therapy methods and agents

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070160571A1 (en) * 2006-01-11 2007-07-12 Mitchell Krathwohl Composition and method for inducing protective vaccine response
RU2573912C2 (ru) * 2008-10-08 2016-01-27 Интрексон Корпорейшн Сконструированные клетки, экспрессирующие множественные иммуномодуляторы, и их применения
US11236139B2 (en) * 2014-11-05 2022-02-01 The Regents Of The University Of California Combination immunotherapy
AU2017290828A1 (en) * 2016-06-30 2019-01-24 Virogin Biotech Canada Ltd Pseudotyped oncolytic viral delivery of therapeutic polypeptides
WO2018191619A1 (en) * 2017-04-13 2018-10-18 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
EP3731850A4 (en) * 2017-12-29 2021-12-01 Oncorus, Inc. ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES

Similar Documents

Publication Publication Date Title
Zhang et al. Advances in cancer immunotherapy: historical perspectives, current developments, and future directions
Gatti-Mays et al. Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations
Wang et al. Therapeutic strategies to remodel immunologically cold tumors
Davey et al. Metastatic melanoma treatment: Combining old and new therapies
Kim et al. Past, present, and future of anticancer nanomedicine
JP2017538680A5 (enExample)
FI3728313T3 (fi) Syövän yhdistelmähoito IAP-antagonistilla ja anti-PD-1-molekyylillä
KR102308798B1 (ko) 다양한 암의 면역요법 치료에서의 사용을 위한 펩티드, 펩티드의 조합 및 골격
JP2022500419A5 (enExample)
JP2022542802A5 (enExample)
Dimberu et al. Cancer immunotherapy takes a multi-faceted approach to kick the immune system into gear
CA2321161A1 (en) Compositions containing an ox-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response
JP2022507744A5 (enExample)
Haddad et al. Using viral vectors to deliver local immunotherapy to glioblastoma
Pierini et al. Trial watch: DNA-based vaccines for oncological indications
Catani et al. Intratumoral immunization by p19Arf and interferon-β gene transfer in a heterotopic mouse model of lung carcinoma
JP2019517508A5 (enExample)
Kubicek et al. Phase I trial using the proteasome inhibitor bortezomib and concurrent chemoradiotherapy for head-and-neck malignancies
Chang et al. Vaccinating against cancer: getting to prime time
Maletzki et al. Chemo-immunotherapy improves long-term survival in a preclinical model of MMR-D-related cancer
Wang et al. Current status and progress of the development of prostate cancer vaccines
Chekaoui et al. Cancer vaccines: an update on recent achievements and prospects for cancer therapy
Berraondo et al. Immunogenicity and efficacy of personalized adjuvant mRNA cancer vaccines
Fatemi et al. Emerging frontiers in colorectal cancer therapy: From targeted molecules to immunomodulatory breakthroughs and cell-based approaches
Sultan et al. Precision oncolytic viral therapy in colorectal cancer: Genetic targeting and immune modulation for personalized treatment